Real-World Experience in the Clinical Use of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Taiwan: A Post-Marketing Surveillance Study

Background: Idiopathic pulmonary fibrosis (IPF) is a serious, progressive lung disease for which treatments are scarce. Pirfenidone has been approved for the treatment of IPF in Taiwan since 2016. This study aimed to gain a better insight into pirfenidone’s real-world safety and effectiveness in adu...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Ping-Hung Kuo, Chih-Yen Tu, Chia-Hung Chen, Kuo-Chin Kao, Jeng-Yuan Hsu, Meng-Chih Lin, Inn-Wen Chong, Chau-Chyun Sheu
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Subjects:	pirfenidone idiopathic pulmonary fibrosis Taiwan safety forced vital capacity real-world registry
Online Access:	https://www.mdpi.com/2227-9059/12/10/2348